PURPOSE: Based on MIT NEWDIGS LEAPS Project experience, inspire participants to explore Adaptive Reimbursement opportunities to accelerate adoption of RWE-based patient regimen optimization to simultaneously improve quality-of-life and economic outcomes.

DESCRIPTION: Scientific, clinical development and regulatory advancements are fueling unprecedented biopharmaceutical innovation from gene therapies to immunotherapies. These upstream innovations have not been matched by patient-centered downstream innovations that employ payment and other incentive systems to implement patient specific regimen improvements informed by leveraging real-world evidence.

Adaptive reimbursement combines downstream innovations that:

1. Creatively cover and finance therapies to ensure timely, appropriate access, enhance healthcare system sustainability and reward upstream innovation; and
2. Reward optimized treatment regimens for each patient through the generation of real-world evidence that reduces uncertainties regarding biopharmaceutical product performance.

This Panel will explore current Adaptive Reimbursement examples from the MIT NEWDIGS LEAPS project, discuss developing future innovations, and describe approaches to overcome the significant implementation challenges. Hear how:

• Durable cell and gene therapy precision financing models could apply to other therapeutic areas
• Adaptive reimbursement mechanisms might fund RWE production platforms (indirectly or directly) by creating financial demand for their results
• Data needed to administer adaptive reimbursement contracts can also be used to de-risk market access, identify unmet medical needs, and monitor patient benefits from therapies
• RWE platforms could fuel the design and implementation of innovative adaptive reimbursement models